Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
Earnings for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
Earnings in 2023 (TTM): $1.31 B
According to Sun Pharmaceutical Industries Limited's latest financial reports the company's current earnings (TTM) are $1.31 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Sun Pharmaceutical Industries Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $1.31 B | $1.13 B |
| 2022 | $1.11 B | $1 B |
| 2021 | $531.01 M | $387.8 M |
| 2020 | $331.71 M | $344.09 M |
| 2019 | $593.61 M | $446.12 M |
| 2018 | $451.49 M | $315.84 M |
| 2017 | $412.24 M | $256.13 M |
| 2016 | $1.07 B | $825.24 M |
| 2015 | $801.65 M | $558.81 M |
| 2014 | $758.71 M | $537.89 M |
| 2013 | $543.07 M | $372.25 M |
| 2012 | $512.06 M | $353.48 M |
| 2011 | $397.72 M | $306.57 M |
| 2010 | $241.23 M | $215.19 M |
| 2009 | $167.65 M | $159.61 M |
| 2008 | $230.97 M | $222.53 M |
| 2007 | $189.52 M | $183.77 M |
| 2006 | $98.76 M | $99.55 M |
| 2005 | $70.73 M | $67.89 M |
| 2004 | $49.87 M | $47.45 M |
| 2003 | $45.17 M | $39.2 M |